Men with prostate cancer who smoke have an associated increased risk of all-cause, cardiovascular, and prostate cancer-specific death, say the authors of a study from the Harvard School of Public Health, Boston.
Men with prostate cancer who smoke have an associated increased risk of all-cause, cardiovascular, and prostate cancer-specific death, say the authors of a study from the Harvard School of Public Health, Boston.
Smokers in the study also had an increased likelihood of prostate cancer recurrence, the researchers reported in JAMA (2011; 305:2548-55).
"In our study, we found similar results for both prostate cancer recurrence and prostate cancer mortality," said lead author Stacey Kenfield, ScD. "These data taken together provide further support that smoking may increase risk of prostate cancer progression."
Dr. Kenfield and colleagues conducted a prospective observational study of 5,366 men diagnosed with prostate cancer between 1986 and 2006 in the Health Professionals Follow-Up Study. The researchers documented 1,630 deaths, 524 (32%) due to prostate cancer, 416 (26%) due to cardiovascular disease, and 878 prostate cancer recurrences.
Men with prostate cancer who were current smokers were found to have a 61% increased risk of dying from prostate cancer and a 61% higher risk of recurrence compared with men who never smoked.
Compared with current smokers, men who had quit smoking for 10 or more years had prostate cancer mortality risks similar to those who had never smoked.
EV/pembrolizumab under review in China for advanced urothelial carcinoma
March 28th 2024The sBLA is supported by findings from the phase 3 EV-302 trial, which showed that EV/pembrolizumab extended overall survival and progression-free survival vs platinum-based chemotherapy in patients with advanced urothelial carcinoma.
Potential code for prior authorizations on AMA CPT Editorial Panel meeting agenda
March 28th 2024"Good public and economic policy must align costs, benefits, and incentives; currently, all costs are incurred by physician practices, and all financial savings and benefits from prior authorization accrue to health insurance plans, leading to perverse incentives,” says Alex Shteynshlyuger, MD.